Institute of Hematology & Blood Diseases Hospital, China: Anemia, Aplastic trials

The registry lists 28 Anemia, Aplastic studies with Institute of Hematology & Blood Diseases Hospital, China as lead sponsor. 17 are open to participants now and 0 have results posted.

Phase 1 5Phase 2 16No phase 10(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Phase I/II Study of Anti-CD38 Monoclonal Antibody in Refractory Severe Aplastic AnemiaRecruitingNCT07714512Phase 1/2
• Brain Cognitive Network Abnormalities in Anemia Patients Using fNIRSRecruitingNCT07578675
• Adverse Effects of ATG/ALG Therapy in Aplastic AnemiaRecruitingNCT07461116
• HID-HSCT Versus IST as First-line Treatment for SAANot yet recruitingNCT07338422Not applicable
• Safety and Efficacy of the JAK1 Inhibitor Combined With Intensive Immunosuppressive Therapy in Severe Aplastic AnemiaNot yet recruitingNCT07297550Phase 1/2
• The Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic AnemiaNot yet recruitingNCT07287228Phase 1/2
• Efficacy and Safety of UCBT With TMI -Based Conditioning Regimen for Adults With Refractory/Relapsed Aplastic AnemiaNot yet recruitingNCT07078721Phase 2
• Dose-attenuated IST and Hetrombopag in Elderly (≥65 Years) Patients With Severe Aplastic AnemiaRecruitingNCT07010237Phase 2
• Reproductive and Mental Health of Patients With Aplastic AnemiaRecruitingNCT06936930
• Reduced-dose Conditioning Regimen Containing TBI in HSCT Treating Elderly Patients With Aplastic AnemiaNot yet recruitingNCT06769568Phase 2
• Reduced Dose of Cyclophosphamide Combined With Standard Immunosuppressive Therapy to Treat Severe Aplastic AnemiaRecruitingNCT06695741Phase 2
• CD7 CAR T Cells (RD13-02) in the Treatment of Relapsed/Refractory Severe Aplastic AnemiaRecruitingNCT06622694Phase 1
• Standard Immunosuppressive Therapy Combined With Romiplostim N01 as First-line Treatment for Severe Aplastic AnemiaRecruitingNCT06613880Phase 2
• Rituximab for Serious Aplastic Anemia With Platelet Transfusion RefractorinessRecruitingNCT06254560Phase 2
• Efficacy and Safety of Avatrombopag vs. Avatrombopag Combined With rhTPO in the Treatment of SAANot yet recruitingNCT06254287Phase 2
• The Safety and Efficacy Study of Avatrombopag Switch in TPO-RA Refractory AARecruitingNCT05518331Not applicable
• National Longitudinal Cohort of Hematological DiseasesRecruitingNCT04645199
• Clinical Study of UC-MSC Combined With Immunosuppressive Agents in the Treatment of Pediatric HAAACompletedNCT07850362Not applicable
• Cyclophosphamide Added to Standard Immunosuppressive Therapy With Herombopag as Front-line Therapy in Patients With Severe Aplastic AnemiaActive, not recruitingNCT05975996Phase 2
• Efficacy of Daratumumab to Overcome Platelet Transfusion Refractoriness in Patients with Aplastic AnemiaCompletedNCT05832216Phase 1
• Avatrombopag Combined With IST as First-line Treatment for SAAStatus unknownNCT05720234Phase 2
• Efficacy and Safety of Avatrombopag Combined With IST for the Treatment of HAAA and SAA With Abnormal Liver FunctionStatus unknownNCT05571332Not applicable
• A Study of PEG-rhG-CSF and rhG-CSF Used for Aplastic Anemia Granulocyte DeficiencyStatus unknownNCT05531279Not applicable
• Efficacy and Safety of CSA and Avatrombopag for the Treatment of SAA in the ElderlyStatus unknownNCT05433922Not applicable
• Efficacy and Safety of Low-dose Decitabine in Refractory Aplastic AnemiaTerminatedNCT04854889Phase 2
• A Single-Arm Phase 2 Study With Optimized Standard Protocol for Severe Aplastic AnemiaCompletedNCT02203396Phase 2
• Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013)Status unknownNCT01760096Phase 2
• Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal HemoglobinuriaStatus unknownNCT01642979Phase 2